EPAS1 and neoplasm: ~70% of RCC patients exhibit deletions or loss-of-function mutations of the vhl gene [5, 34, 35], which is a tumor suppressor and functions as a ubiquitin E3 ligase of HIF1α and HIF2α proteins.